HealthDay News — The US Food and Drug Administration has issued 7 warning letters to companies illegally marketing products containing 7-hydroxymitragynine (7-OH), which is found in trace amounts in ...

HealthDay News — In a study published online July 9 in Blood Cancer Discovery, real-world outcomes are described for teclistamab, a T-cell-engaging bispecific antibody that targets multiple myeloma ...

“Anticholinergics are associated with numerous adverse outcomes in older adults; therefore, it is essential for clinicians to avoid their use when possible, prescribe the lowest effective dose, and ...

The Food and Drug Administration (FDA) has granted Priority Review to TAR-200 for the treatment of patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle invasive bladder ...

HealthDay News — Only 34% of patients with erythema migrans greater than 5cm are positive for Lyme disease by a standard 2-tier testing (STTT) algorithm, and of patients continuing to experience ...

In response to the CRL, the Company initiated a randomized, double-masked, vehicle-controlled dry eye chamber trial.

Greer Donley, a law professor at the University of Pittsburgh, said the ruling could change how states regulate other FDA-approved medication, including vaccines.

Better control of nocturnal blood pressure and improved circadian rhythm seen with bedtime versus daytime dosing.

HealthDay News — Data released this week by the World Health Organization and UNICEF indicate modest gains in childhood vaccination rates, but globally, more than 14 million children remain ...

While officials pointed to the department’s $1.8 trillion budget as a reason for the cuts, experts said payroll represented less than 1% of that amount.

Nostrum Labs is recalling all lots within expiry of Sucralfate Tablets 1g as the Company has shut down operations at its US sites and is unable to assure the quality of the product.

The amended dosing regimen was approved based on results from a post hoc analysis of the phase 2 MagnetisMM-3 trial.